United States Market for Ankylosing Spondylitis Pharmacotherapy

Low Disease Awareness Results in Substantial Untapped Market

Regular Price: USD 4,950

Special Price USD 3,713

25% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,713

PAY BY INVOICE

Be the first to review this product

This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics.

Table of Contents

United States Market for Ankylosing Spondylitis Pharmacotherapy, Ankylosing Spondylitis Pharmacotherapeutics MarketAnalysis of the Ankylosing Spondylitis Pharmacotherapeutics Market in the United StatesExecutive Summary and Market OverviewUnited States Market for Ankylosing Spondylitis Pharmacotherapy, Ankylosing Spondylitis Pharmacotherapeutics Market - Total Ankylosing Spondylitis Pharmacotherapeutics MarketAnalysis of the Total Ankylosing Spondylitis Pharmacotherapeutics MarketDrivers and RestraintsForecasts and TrendsDemand AnalysisMarket Share and Competitive AnalysisUnited States Market for Ankylosing Spondylitis Pharmacotherapy, TNF Inhibitor SegmentAnalysis of the TNF Inhibitor SegmentSegment Breakdown and Market Engineering MeasurementsPatient ForecastPricing Trends and ForecastRevenue ForecastMarket Share AnalysisUnited States Market for Ankylosing Spondylitis Pharmacotherapy, Non-TNF Biologics SegmentAnalysis of the Non-TNF Biologics SegmentSegment BreakdownPatient ForecastPricing Trends and ForecastRevenue ForecastUnited States Market for Ankylosing Spondylitis Pharmacotherapy, The Last WordThe Last WordSummary and ConclusionsUnited States Market for Ankylosing Spondylitis Pharmacotherapy, AppendixAppendixAppendix




Related Research

Release Date : 21-Sep-17

Region : North America

Release Date : 21-Sep-17

Region : North America

Release Date : 21-Sep-17

Region : North America

Release Date : 21-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.